PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4111-4126

  Vuppugalla, Ragini ^a   Marathe, Punit ^a   He, Handan ^b   Jones, Rhys D O ^c   Yates, James W T ^c   Jones, Hannah M ^d   Gibson, Christopher R ^e   Chien, Jenny Y ^f   Ring, Barbara J ^f   Adkison, Kimberly K ^g   Ku, M Sherry ^h   Fischer, Volker ⁱ   Dutta, Sandeep ⁱ   Sinha, Vikash K ^j   Björnsson, Thorir ^k   Lavé, Thierry ^l   Poulin, Patrick ^m  

^a BRISTOL MYERS SQUIBB   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c ASTRAZENECA   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g GLAXOSMITHKLINE   (United States)

^h Anchen Pharmaceuticals Inc   (United States)

ⁱ ABBOTT LABORATORIES   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^k CRITICAL PATH INSTITUTE   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m F Hoffmann La Roche Ltd ^*  (Canada)

more..

Author keywords

Absorption; Allometry; Clearance; Computational ADME; Disposition; Distribution; First time in human; PBPK; Pharmacokinetics; QSAR

Indexed keywords

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SIMULATION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ACCESS TO INFORMATION; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; COOPERATION; DOG; DRUG DATABASE; DRUG DEVELOPMENT; DRUG SCREENING; EVALUATION STUDY; GASTROINTESTINAL ABSORPTION; INTERDISCIPLINARY COMMUNICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; REPRODUCIBILITY; SPECIES DIFFERENCE; STATISTICAL MODEL;

DRUG;

ACCESS TO INFORMATION; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; COOPERATIVE BEHAVIOR; DATABASES, PHARMACEUTICAL; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL ABSORPTION; HUMANS; INTERDISCIPLINARY COMMUNICATION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

EID: 80052258840     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22551     Document Type: Article

References (29)

1. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D. 2007. On the anticipation of the human dose in First in man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37:1331-1354.
2. Huang C, Zheng M, Yang Z, Rodrigues AD, Marathe P. 2008. Projection of exposure and efficacious dose prior to first in human studies: How successful have we been? Pharm Res 25;713-726.
3. Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G. 2009. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: Strategic considerations. Drug Discov Today 14;358-372.
4. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
5. Mahmood I. 2006. Prediction of human drug clearance from animal data: Application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). J Pharm Sci 95:1810-1821.
6. Fura A, Vyas V, Humphreys W, Chimalokonda A, Rodrigues D. 2008. Prediction of human oral pharmacokinetics using nonclinical data: Examples involving four proprietary compounds. Biopharm Drug Dispos 29:455-468.
7. Dedrick R, Bischoff KB, Zaharko DS. 1970. Interspecies correlation of plasma concentration history of methotrexate (NSC740). Cancer Chemother Rep 54:95-101.
8. DeBuck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. 2007. Prediction of human pharmacokinetics using Physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780.
9. Jones HM, Parrott N, Ohlenbusch G, Lave T. 2006. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin Pharmacokinet 45:1213-1226.
10. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 Suppl 1:S41-S67.
11. Jamei M, Marciniak F, Feng K, Barnett A, Tucker G, RostamiHogjegan A. 2009. The Simcyp populationbased ADME simulator. Expert Opin Drug Metab Toxicol 2:211-223.
12. Poulin P, Jones RDO, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fisher V, Dutta S, Sinha VK, Björnsson T, Lavé T, Yates JWT. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 5. Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic (PBPK) approach. J Pharm Sci (submitted as a companion paper).
13. Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890-1900.
14. Shimamura K, Wajima T, Yano Y. 2007. Pharmacokinetic prediction for intravenous betalactam antibiotics in pediatric patients. J Pharm Sci 96:3125-3139.
15. Poulin P, Jones HM, Jones RDO, Yates JWT, Gibson CR, Chien JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P, Fisher V, Dutta S, Sinha VK, Björnsson T, Lavé T, Ku MS. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 1. Goals, properties of the PhRMA dataset and comparison with literature datasets. J Pharm Sci (submitted as a companion paper).
16. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fisher V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 3. Comparative assessment of prediction methods of human clearance. J Pharm Sci (submitted as a companion paper).
17. Jones RDO, Jones HM, Rowland M, Gibson CR, Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fisher V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 2. Comparative assessment of prediction methods of human volume of distribution. J PharmSci (submitted as a companion paper).
18. Tang H, Mayersohn M. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303.
19. Wajima T, Fukumura K, Yano Y, Oguma T. 2002. Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91:2489-2499.
20. Øie S, Tozer TN. 1979. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203-1205.
21. Wajima T, Fukumura K, Yano Y, Oguma T. 2003. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: Volume of distribution at steady state. J Pharm Pharmacol 55:939-949.
22. Jansson R, Bredberg U, Ashton M. 2008. Prediction of drug tissue to plasma concentration ratios using ameasured volume of distribution in combination with lipophilicity. J Pharm Sci 97:2324-2339.
23. Poulin P, Ekin S, Theil FP. 2011. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 250: 194-212.
24. Fagerholm U. 2007. Prediction of human pharmacokinetics: Evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 59:1181-1190.
25. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. 2009. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
26. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. 2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893.
27. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45(5):511-542.
28. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I. 2003. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233-243.
29. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686.